HeartSciences (HSCS) Net Income towards Common Stockholders (2021 - 2026)

HeartSciences (HSCS) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$2.8 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 31.57% year-over-year to -$2.8 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$22.5 million (up 55.8% YoY) and the FY2026 annual result came in at -$25.8 million, down 10.19% from the prior year.
• Net Income towards Common Stockholders eased to -$2.8 million in Q2 2026, from -$2.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.2 million in Q1 2022 to a low of -$17.3 million in Q3 2025.
• A 5-year average of -$9.3 million and a median of -$12.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 1476.03% — and 2025, when it surged 85.34%.
• Tracing HSCS's Net Income towards Common Stockholders over 5 years: stood at -$12.5 million in 2022, then retreated by 11.23% to -$14.0 million in 2023, then dropped by 15.02% to -$16.0 million in 2024, then surged by 85.34% to -$2.4 million in 2025, then fell by 17.5% to -$2.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.8 million (Q2 2026), -$2.4 million (Q4 2025), and -$17.3 million (Q3 2025), per Business Quant data.